A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers
← catalyst calendarNCT06453187 · readout in 134 d
Sponsored by Integra LifeSciences Corporation (industry) · IART — their whole pipeline →. With SerenaGroup, Inc..
Phase
Not applicable
Status
Enrolling by invitation
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
350estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-18 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetic Foot Ulcer
- Venous Leg Ulcer
Interventions
- Device: Urinary Bladder Matrix (UBM) sheet device for Venous Leg Ulcers
- Device: Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot Ulcers
- Device: AmnioExcel Plus for Venous Leg Ulcers
- Device: AmnioExcel Plus for Diabetic Foot Ulcers
- Procedure: Standard of Care
Primary outcome
what the primary-completion date above is the date OFPercentage of complete wound closure for target ulcer
measured 1-12 weeks
Permalink · IART's whole pipeline · Catalyst calendar · Every registered study · What changed